On October 15th, two Myanmarese doctors from Department of Medical Research (Lower Myanmar) visited Nichinichi Pharmaceutical Co. Ltd. to report on the progression of an ongoing clinical study in Myanmar on chronic hepatitis C using FK-23.
The clinical test has been performed against 46 Myanmarese hepatitis C carriers for three years. In the report, they announced the possibility of FK-23 on the clinical application to chronic hepatitis C, since it was showed that the intake of FK-23 significantly reduced the ALT and AST levels (liver function marker) at three months after the intake and maintained their lower levels during the test. Doctors then inspected our facilities such as the manufacturing plant and the quality control procedures.
They showed their interests in the manufacturing process and the quality control procedures for the high quality raw materials.